TITLE: ADVERSE DRUG REACTIONS AND DRUG–DRUG INTERACTIONS ASSOCIATED WITH CIMETIDINE: AN ADR STUDY AND PHARMACOVIGILANCE REVIEW
AUTHOR(S): Mr. Dattatray D. Kumbhar*, Mr. Tanaji K. Zore, Mr. Prathmesh M. Yadav, Ms. Samruddhi M. Patil, Dr. Shobhraj B. Malavi, Mr. Umesh B. Kolap, Dr. Sandip S. Biradar
Abstract:
Background: Cimetidine, a first-generation histamine H₂-receptor antagonist, has been widely used for the management of acid-related gastrointestinal disorders for several decades. Despite its long-standing clinical use and perceived safety, accumulating evidence indicates that cimetidine is associated with a broad spectrum of adverse drug reactions (ADRs) and clinically relevant drug–drug interactions.
Objective: This narrative review aims to comprehensively summarize the pharmacological basis, clinical manifestations, and mechanistic pathways underlying adverse reactions and drug–drug interactions associated with cimetidine.
Methods: A narrative synthesis of published clinical reports, case studies, pharmacokinetic analyses, and mechanistic investigations was undertaken to evaluate hepatic, renal, neurological, metabolic, immunological, and hypersensitivity-related adverse effects of cimetidine, along with its interaction potential.
Results: Cimetidine-induced toxicity is mediated through both pharmacokinetic mechanisms—primarily cytochrome P450 inhibition—and immunomodulatory effects. Rare but serious complications include autoimmune-like hepatitis, ANCA-associated acute tubulointerstitial nephritis, acute dystonic reactions, metabolic derangements such as lactic acidosis, and severe drug–drug interactions involving agents with narrow therapeutic indices. Emerging evidence challenges the traditional view of cimetidine as a benign therapy, particularly in vulnerable populations.
Conclusion: Although most cimetidine-associated adverse effects are uncommon, several can be severe or life-threatening. Increased clinical awareness, careful patient selection, and vigilant monitoring are essential to mitigate risks, especially given its continued over-the-counter availability.
Keywords:
Cimetidine; adverse drug reactions; drug–drug interactions; cytochrome P450 inhibition; autoimmune-like hepatitis; ANCA-associated tubulointerstitial nephritis; dystonia; lactic acidosis; pharmacovigilance.
Introduction:
Beyond its effects on drug metabolism, cimetidine also exhibits immunomodulatory properties that may contribute to uncommon but clinically relevant immune-mediated adverse reactions[12]. Experimental and clinical evidence suggests that cimetidine can enhance cell-mediated immune responses, suppress regulatory T-cell activity, and stimulate immunoglobulin production[13]. These immunological alterations may predispose susceptible individuals to hypersensitivity reactions, autoimmune phenomena, or immune-mediated hematological disorders[14]. Collectively, the combined impact of CYP enzyme inhibition and immune system modulation provides a mechanistic explanation for the adverse reactions and drug interaction potential associated with cimetidine, emphasizing the need for careful patient selection, dose adjustment, and monitoring during therapy.
Hepatotoxicity and Autoimmune-Like Liver Injury
Although relatively rare, hepatotoxicity associated with cimetidine has been documented in the literature and may manifest as hepatocellular, cholestatic, or mixed patterns of liver injury[15]. The onset of hepatic dysfunction is variable, with latency periods ranging from a few days to several months after initiation of therapy, suggesting both dose-independent and idiosyncratic mechanisms[16]. Clinical presentation may include asymptomatic elevations in liver enzymes or overt features of liver injury, underscoring the importance of biochemical monitoring in susceptible individuals[17].
In exceptional cases, cimetidine has been implicated in the development of autoimmune-like hepatitis. These cases are characterized by the presence of circulating autoantibodies, histopathological findings of interface hepatitis with prominent lymphocytic portal infiltration, and a clinical course resembling idiopathic autoimmune hepatitis[18]. A notable feature of this presentation is the favorable response to corticosteroid therapy, which strongly supports an immune-mediated pathogenesis[19]. Prompt recognition and withdrawal of the offending agent, along with timely initiation of immunosuppressive treatment when indicated, are crucial to prevent progression to chronic liver disease or long-term hepatic sequelae[20].
Renal Toxicity and Immuno-Renal Complications
Cimetidine has been associated with both functional and immune-mediated renal adverse effects[21]. A well-recognized and generally benign effect is a reversible elevation in serum creatinine resulting from inhibition of tubular creatinine secretion, which occurs without an actual reduction in glomerular filtration rate (GFR)[22]. This pharmacokinetic interaction
may mimic acute kidney injury (AKI) biochemically and should be distinguished from true renal parenchymal damage to avoid unnecessary discontinuation or intervention[23].
In contrast, cimetidine has also been implicated in true inflammatory renal injury, most notably acute tubulointerstitial nephritis (ATIN)[24]. Emerging evidence suggests that cimetidine may act as a trigger for antineutrophil cytoplasmic antibody (ANCA)–associated ATIN[25]. A landmark case described a 70-year-old woman who developed persistent AKI following cimetidine exposure, accompanied by markedly elevated myeloperoxidase-ANCA (MPO-ANCA) levels[26]. Renal biopsy revealed diffuse tubulointerstitial inflammation with prominent neutrophilic infiltration and peritubular capillaritis, in the absence of glomerular involvement[27]. Unlike classical drug-induced hypersensitivity ATIN, renal dysfunction and ANCA positivity persisted despite drug withdrawal, necessitating immunosuppressive therapy[28]. Treatment with systemic corticosteroids, specifically prednisolone, resulted in gradual recovery of renal function and serological remission[29].
References
1. Majhi A, Sinha A, Pal A, Hossain A, Dutta D, Erfanul S. Targeting histamine signaling in inflammation and allergy: A mechanistic and therapeutic review. https://doi.org/10.30574/wjbphs.2025.23.1.0655
2. Kou E, Zhang X, Dong B, Wang B, Zhu Y. Combination of H1 and H2 histamine receptor antagonists: current knowledge and perspectives of a classic treatment strategy. Life. 2024 Jan 23;14(2):164. https://doi.org/10.3390/life14020164
3. Kuna L, Jakab J, Smolic R, Raguz-Lucic N, Vcev A, Smolic M. Peptic ulcer disease: a brief review of conventional therapy and herbal treatment options. Journal of clinical medicine. 2019 Feb 3;8(2):179. https://doi.org/10.3390/jcm8020179
4. Lim SY, Al Bishtawi B, Lim W. Role of cytochrome P450 2C9 in COVID-19 treatment: current status and future directions. European Journal of Drug Metabolism and Pharmacokinetics. 2023 May;48(3):221-40. https://doi.org/10.1007/s13318-023-00826-8
5. Dobrek L. A synopsis of current theories on drug-induced nephrotoxicity. Life. 2023 Jan 24;13(2):325. https://doi.org/10.3390/life13020325
6. Bellanca CM, Augello E, Cantone AF, Di Mauro R, Attaguile GA, Di Giovanni V, Condorelli GA, Di Benedetto G, Cantarella G, Bernardini R. Insight into risk factors, pharmacogenetics/genomics, and management of adverse drug reactions in elderly: a narrative review. Pharmaceuticals. 2023 Nov 1;16(11):1542. https://doi.org/10.3390/ph16111542
7. Kou E, Zhang X, Dong B, Wang B, Zhu Y. Combination of H1 and H2 histamine receptor antagonists: current knowledge and perspectives of a classic treatment strategy. Life. 2024 Jan 23;14(2):164. https://doi.org/10.3390/life14020164
8. Sitsen JM, Maris FA, Timmer CJ. Concomitant use of mirtazapine and cimetidine: a drug–drug interaction study in healthy male subjects. European journal of clinical pharmacology. 2000 Aug;56(5):389-94. https://doi.org/10.1007/s002280000174
9. Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, Huai C, Shen L, Zhang N, He L, Qin S. Cytochrome P450 enzymes and drug metabolism in humans. International journal of molecular sciences. 2021 Nov 26;22(23):12808. https://doi.org/10.3390/ijms222312808
10. Fuhr U. Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans. Clinical pharmacokinetics. 2000 Jun;38(6):493-504. https://doi.org/10.2165/00003088-200038060-00003
11. Tamargo J, Le Heuzey JY, Mabo P. Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. European journal of clinical pharmacology. 2015 May;71(5):549-67. https://doi.org/10.1007/s00228-015-1832-0
12. Uetrecht J. Immune-mediated adverse drug reactions. Chemical research in toxicology. 2009 Jan 19;22(1):24-34. https://doi.org/10.1021/tx800389u
13. Kumar A. Cimetidine: an immunomodulator. Dicp. 1990 Mar;24(3):289-95. https://doi.org/10.1177/106002809002400316
14. Starshinova AA, Savchenko AA, Borisov A, Kudryavtsev I, Rubinstein A, Dovgalyuk I, Kulpina A, Churilov LP, Sobolevskaia P, Fedotkina T, Kudlay D. Immunological disorders: gradations and the current approach in laboratory diagnostics. Pathophysiology. 2025 Apr 18;32(2):17. https://doi.org/10.3390/pathophysiology32020017
15. García Rodríguez LA, Wallander MA, Stricker BH. The risk of acute liver injury associated with cimetidine and other acid‐suppressing anti‐ulcer drugs. British journal of clinical pharmacology. 1997 Feb;43(2):183-8. https://doi.org/10.1046/j.1365-2125.1997.05268.x
16. Lemmer P, Sowa JP, Bulut Y, Strnad P, Canbay A. Mechanisms and aetiology‐dependent treatment of acute liver failure. Liver International. 2025 Mar;45(3):e15739. https://doi.org/10.1111/liv.15739
17. Malakouti M, Kataria A, Ali SK, Schenker S. Elevated liver enzymes in asymptomatic patients–what should I do?. Journal of clinical and translational hepatology. 2017 Sep 21;5(4):394. doi: 10.14218/JCTH.2017.00027
18. Zeni N, Cristofani A, Piano SS, Bolognesi M, Romano A. Pathophysiological Differences and Differential Diagnosis of Autoimmune and Drug-Induced Hepatitis. Livers. 2025 May 13;5(2):22. https://doi.org/10.3390/livers5020022
19. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Annals of internal medicine. 1993 Dec 15;119(12):1198-208. https://doi.org/10.7326/0003-4819-119-12-199312150-00007
20. Gabrielli F, Bernasconi E, Toscano A, Avossa A, Cavicchioli A, Andreone P, Gitto S. Side effects of immunosuppressant drugs after liver transplant. Pharmaceuticals. 2025 Feb 27;18(3):342. https://doi.org/10.3390/ph18030342
21. Hess DA, Rieder MJ. The role of reactive drug metabolites in immune-mediated adverse drug reactions. Annals of Pharmacotherapy. 1997 Nov;31(11):1378-87. https://doi.org/10.1177/106002809703101116
22. Capelouto CC, Saltzman B. The pathophysiology of ureteral obstruction. Journal of endourology. 1993 Apr;7(2):93-103. https://doi.org/10.1089/end.1993.7.93
23. Pickkers P, Darmon M, Hoste E, Joannidis M, Legrand M, Ostermann M, Prowle JR, Schneider A, Schetz M. Acute kidney injury in the critically ill: an updated review on pathophysiology and management. Intensive care medicine. 2021 Aug;47(8):835-50. https://doi.org/10.1007/s00134-021-06454-7
24. Morimoto K, Kanzaki G, Niikura T, Koike K, Matsuo N, Maruyama Y, Tsuboi N, Yokoo T. Acute tubulointerstitial nephritis associated with antineutrophil cytoplasmic antibody following cimetidine treatment: a case report. BMC nephrology. 2021 Aug 30;22(1):294. https://doi.org/10.1186/s12882-021-02502-y
25. Bonaci-Nikolic B, Nikolic MM, Andrejevic S, Zoric S, Bukilica M. Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides. Arthritis research & therapy. 2005 Jul 13;7(5):R1072. https://doi.org/10.1186/ar1789
26. Morimoto K, Kanzaki G, Niikura T, Koike K, Matsuo N, Maruyama Y, Tsuboi N, Yokoo T. Acute tubulointerstitial nephritis associated with antineutrophil cytoplasmic antibody following cimetidine treatment: a case report. BMC nephrology. 2021 Aug 30;22(1):294. https://doi.org/10.1186/s12882-021-02502-y
27. Jacq A, Tarris G, Jaugey A, Paindavoine M, Maréchal E, Bard P, Rebibou JM, Ansart M, Calmo D, Bamoulid J, Tinel C. Automated evaluation with deep learning of total interstitial inflammation and peritubular capillaritis on kidney biopsies. Nephrology Dialysis Transplantation. 2023 Dec;38(12):2786-98. https://doi.org/10.1093/ndt/gfad094
28. Paueksakon P, Fogo AB. Drug‐induced nephropathies. Histopathology. 2017 Jan;70(1):94-108. https://doi.org/10.1111/his.13064
29. Saeki T, Kawano M, Mizushima I, Yamamoto M, Wada Y, Ubara Y, Nakashima H, Ito T, Yamazaki H, Narita I, Saito T. Recovery of renal function after glucocorticoid therapy for IgG4-related kidney disease with renal dysfunction. Clinical and Experimental Nephrology. 2016 Feb;20(1):87-93. https://doi.org/10.1007/s10157-015-1140-0
30. Kanigicherla DA, Hamilton P, Czapla K, Brenchley PE. Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New‐incident and relapsing primary membranous nephropathy. Nephrology. 2018 Jan;23(1):60-8. https://doi.org/10.1111/nep.12955
31. Belliere J, Mazieres J, Meyer N, Chebane L, Despas F. Renal complications related to checkpoint inhibitors: diagnostic and therapeutic strategies. Diagnostics. 2021 Jun 30;11(7):1187. https://doi.org/10.3390/diagnostics11071187
32. Sawyer D, Conner CS, Scalley R. Cimetidine: adverse reactions and acute toxicity. American Journal of Hospital Pharmacy. 1981 Feb 1;38(2):188-97. https://doi.org/10.1093/ajhp/38.2.188
33. Sosnowski K, Nehring P, Przybyłkowski A. Pancreas and adverse drug reactions: a literature review. Drug Safety. 2022 Sep;45(9):929-39.
https://doi.org/10.1007/s40264-022-01204-0
34. Criado PR. Adverse drug reactions. InDermatology in Public Health Environments: A Comprehensive Textbook 2023 Apr 1 (pp. 749-806). Cham: Springer International Publishing. https://doi.org/10.1007/978-3-031-13505-7_31
35. Yu Y, Blokhuis BR, Garssen J, Redegeld FA. Non-IgE mediated mast cell activation. European journal of pharmacology. 2016 May 5;778:33-43. https://doi.org/10.1016/j.ejphar.2015.07.017
36. Sawyer D, Conner CS, Scalley R. Cimetidine: adverse reactions and acute toxicity. American Journal of Hospital Pharmacy. 1981 Feb 1;38(2):188-97. https://doi.org/10.1093/ajhp/38.2.188
37. Sawyer D, Conner CS, Scalley R. Cimetidine: adverse reactions and acute toxicity. American Journal of Hospital Pharmacy. 1981 Feb 1;38(2):188-97. https://doi.org/10.1093/ajhp/38.2.188
38. Kurtis MM. Movement Disorders of the Face. InMovement Disorders Curricula 2017 Feb 28 (pp. 389-400). Vienna: Springer Vienna. https://doi.org/10.1007/978-3-7091-1628-9_39
39. Brown TM, Stoudemire A. Psychiatric side effects of prescription and over-the-counter medications: recognition and management. American Psychiatric Pub; 1998.
40. Lennernäs H. Clinical pharmacokinetics of atorvastatin. Clinical pharmacokinetics. 2003 Nov;42(13):1141-60. https://doi.org/10.2165/00003088-200342130-00005
